Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: Young oncologists' perspective

M. Lambertini; A. Toss; A. Passaro; C. Criscitiello; C. Cremolini; C. Cardone; F. Loupakis; G. Viscardi; I. Meattini; M.V. Dieci; R. Ferrara; R. Giusti; M.D. Maio

doi:10.1136/esmoopen-2020-000759

Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: Young oncologists' perspective

M. Lambertini, A. Toss, A. Passaro, C. Criscitiello, C. Cremolini, C. Cardone, F. Loupakis, G. Viscardi, I. Meattini, M.V. Dieci, R. Ferrara, R. Giusti, M.D. Maio

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	ESMO Open
Volume	5
Issue number	2
DOIs	https://doi.org/10.1136/esmoopen-2020-000759
Publication status	Published - 2020

Keywords

editorial
age
Article
cancer growth
cancer immunotherapy
cancer palliative therapy
cancer patient
cancer screening
cancer therapy
caregiver
coronavirus disease 2019
cytokine storm
differential diagnosis
European Medicines Agency
evidence based practice
follow up
Food and Drug Administration
health care personnel
hospital admission
human
infection risk
Italy
malignant neoplasm
medical oncologist
pandemic
risk factor
telemedicine
terminal care
therapy delay
treatment interruption
virus pneumonia
virus transmission
Betacoronavirus
China
Coronavirinae
Coronavirus infection
oncologist
SARS coronavirus
Coronavirus
Coronavirus Infections
Humans
Oncologists
Pandemics
Pneumonia, Viral
SARS Virus

Access to Document

10.1136/esmoopen-2020-000759

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85082730681&doi=10.1136%2fesmoopen-2020-000759&partnerID=40&md5=a13a4acba8b71d1e3943095ad50dbbdb

Cite this

Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: Young oncologists' perspective. / Lambertini, M.; Toss, A.; Passaro, A.; Criscitiello, C.; Cremolini, C.; Cardone, C.; Loupakis, F.; Viscardi, G.; Meattini, I.; Dieci, M.V.; Ferrara, R.; Giusti, R.; Maio, M.D.

In: ESMO Open, Vol. 5, No. 2, 2020.

Research output: Contribution to journal › Article › peer-review

@article{801136255aa745d9be42c61be1cd477b,

title = "Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: Young oncologists' perspective",

keywords = "editorial, age, Article, cancer growth, cancer immunotherapy, cancer palliative therapy, cancer patient, cancer screening, cancer therapy, caregiver, coronavirus disease 2019, cytokine storm, differential diagnosis, European Medicines Agency, evidence based practice, follow up, Food and Drug Administration, health care personnel, hospital admission, human, infection risk, Italy, malignant neoplasm, medical oncologist, pandemic, risk factor, telemedicine, terminal care, therapy delay, treatment interruption, virus pneumonia, virus transmission, Betacoronavirus, China, Coronavirinae, Coronavirus infection, oncologist, SARS coronavirus, Coronavirus, Coronavirus Infections, Humans, Oncologists, Pandemics, Pneumonia, Viral, SARS Virus",

author = "M. Lambertini and A. Toss and A. Passaro and C. Criscitiello and C. Cremolini and C. Cardone and F. Loupakis and G. Viscardi and I. Meattini and M.V. Dieci and R. Ferrara and R. Giusti and M.D. Maio",

note = "Cited By :75 Export Date: 3 March 2021 Correspondence Address: Lambertini, M.; Department of Medical Oncology, Italy; email: matteo.lambertini@unige.it Funding details: Bayer Funding details: Servier Funding details: Amgen Funding details: Roche Italia Funding text 1: Matteo Lambertini acted as consultant for Roche and Lilly, and received speaker honoraria from Roche, Takeda and Theramex outside the submitted work. Angela Toss acted as consultant for Eisai, Roche and Lilly outside the submitted work. Antonio Passaro acted as consultant for AstraZeneca, Agilent/Dako, Bristol-Myers Squibb, Lilly, Merck Sharp & Dohme and Roche. Carmen Criscitiello received speakers{\textquoteright} bureau and had consultancy/advisory role from Lilly, Roche Novartis, and Pfizer outside the submitted work. Chiara Cremolini acted as consultant for Roche, Bayer and Amgen, and received personal fees from Roche, Amgen, Bayer, Servier, and research funding from Merck Serono. Icro Meattini acted as consultant for Roche, Novartis, and Lilly outside the submitted work. Maria Vittoria Dieci acted as consultant for Eli Lilly, Genomic Health and Celgene outside the submitted work. Raffaele Giusti acted as consultant and received speaker honoraria for Roche and Astra Zeneca outside the submitted work. Massimo Di Maio acted as consultant for Eisai, Takeda, Janssen, Astellas, Pfizer and AstraZeneca, outside the submitted work. The other authors declare no conflicts of interests. References: Zhu, N., Zhang, D., Wang, W., A novel coronavirus from patients with pneumonia in China 2019 (2020) N Engl J Med, 382, pp. 727-733; Lu, R., Zhao, X., Li, J., Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding (2020) Lancet, 395, pp. 565-574; World Health Organization, , https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-At-the-media-briefng-on-covid-19-11-march-2020; Istituto Superiore di Sanit{\`a}, , https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati; Remuzzi, A., Remuzzi, G., Covid-19 and Italy: What next? (2020) Lancet, , [Epub ahead of print: 13 Mar 2020]; (2020) Gazzetta Uffciale della Repubblica Italiana, , https://www.gazzettauffciale.it/eli/gu/2020/03/09/62/sg/pdf; Li, R., Pei, S., Chen, B., Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (sars-cov2) (2020) Science, 6, p. eabb3221; Spina, S., Marrazzo, F., Migliari, M., The response of milan's emergency medical system to the covid-19 outbreak in Italy (2020) Lancet, 395, pp. e49-e50; Grasselli, G., Pesenti, A., Cecconi, M., Critical care utilization for the covid-19 outbreak in lombardy Italy: Early experience and forecast during an emergency response (2020) JAMA, , [Epub ahead of print: 13 Mar 2020]; Murthy, S., Gomersall, C.D., Fowler, R.A., Care for critically ill patients with covid-19 (2020) JAMA, , [Epub ahead of print: 11 Mar 2020]; Wu, Z., McGoogan, J.M., Characteristics of and important lessons from the coronavirus disease 2019 (covid-19) outbreak in China: Summary of a report of 72 314 cases from the chinese center for disease control and prevention (2020) JAMA, , [Epub ahead of print: 13 Mar 2020]; Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2020 (2020) CA Cancer J Clin, 70, pp. 7-30; Kamboj, M., Sepkowitz, K.A., Nosocomial infections in patients with cancer (2009) Lancet Oncol, 10, pp. 589-597; Liang, W., Guan, W., Chen, R., Cancer patients in sars-cov-2 infection: A nationwide analysis in China (2020) Lancet Oncol, 21, pp. 335-337; Xia, Y., Jin, R., Zhao, J., Risk of covid-19 for cancer patients (2020) Lancet Oncol, , [Epub ahead of print: 03 Mar 2020]; Ueda, M., Martins, R., Hendrie, P.C., Managing cancer care during the covid-19 pandemic: Agility and collaboration toward a common goal (2020) J Natl Compr Cancer Netw; Rischio Infettivo da Coronavirus COVID 19: Indicazioni per l'Oncologia da Parte Del Presidente AIOM, Del Presidente Eletto AIOM, Del Presidente CIPOMO e Del Presidente COMU, , https://www.aiom.it/wp-content/uploads/2020/03/20200313-COVID-19-indicazioni-AIOM-CIPOMO-COMU.pdf; Mehta, P., McAuley, D.F., Brown, M., Covid-19: Consider cytokine storm syndromes and immunosuppression (2020) Lancet, , [Epub ahead of print: 16 Mar 2020]; Francesco, C., Pettke, A., Michele, B., Managing covid-19 in the oncology clinic and avoiding the distraction effect (2020) Ann Oncol, , [Epub ahead of print: 19 Mar 2020]; Hollander, J.E., Carr, B.G., Virtually perfect? Telemedicine for covid-19 (2020) N Engl J Med, , [Epub ahead of print: 11 Mar 2020]; Food and Drug Administration (FDA), , https://www.fda.gov/media/136238/download; European Medicines Agency (EMA), , https://www.ema.europa.eu/en/news/guidance-sponsors-how-manage-clinical-trials-during-covid-19-pandemi; Agenzia Italiana Del Farmaco (AIFA), , https://www.aifa.gov.it/documents/20142/871583/Comunicato-gestione-studi-clinici-in-emergenza-COVID-19-EN-12.03.2020.pdf/ee1f33e3-bb3e-9ce9-2a93-b33e88eea94d",

year = "2020",

doi = "10.1136/esmoopen-2020-000759",

language = "English",

volume = "5",

journal = "ESMO Open",

issn = "2059-7029",

publisher = "BMJ Publishing Group",

number = "2",

}

TY - JOUR

T1 - Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: Young oncologists' perspective

AU - Lambertini, M.

AU - Toss, A.

AU - Passaro, A.

AU - Criscitiello, C.

AU - Cremolini, C.

AU - Cardone, C.

AU - Loupakis, F.

AU - Viscardi, G.

AU - Meattini, I.

AU - Dieci, M.V.

AU - Ferrara, R.

AU - Giusti, R.

AU - Maio, M.D.

N1 - Cited By :75 Export Date: 3 March 2021 Correspondence Address: Lambertini, M.; Department of Medical Oncology, Italy; email: matteo.lambertini@unige.it Funding details: Bayer Funding details: Servier Funding details: Amgen Funding details: Roche Italia Funding text 1: Matteo Lambertini acted as consultant for Roche and Lilly, and received speaker honoraria from Roche, Takeda and Theramex outside the submitted work. Angela Toss acted as consultant for Eisai, Roche and Lilly outside the submitted work. Antonio Passaro acted as consultant for AstraZeneca, Agilent/Dako, Bristol-Myers Squibb, Lilly, Merck Sharp & Dohme and Roche. Carmen Criscitiello received speakers’ bureau and had consultancy/advisory role from Lilly, Roche Novartis, and Pfizer outside the submitted work. Chiara Cremolini acted as consultant for Roche, Bayer and Amgen, and received personal fees from Roche, Amgen, Bayer, Servier, and research funding from Merck Serono. Icro Meattini acted as consultant for Roche, Novartis, and Lilly outside the submitted work. Maria Vittoria Dieci acted as consultant for Eli Lilly, Genomic Health and Celgene outside the submitted work. Raffaele Giusti acted as consultant and received speaker honoraria for Roche and Astra Zeneca outside the submitted work. Massimo Di Maio acted as consultant for Eisai, Takeda, Janssen, Astellas, Pfizer and AstraZeneca, outside the submitted work. The other authors declare no conflicts of interests. References: Zhu, N., Zhang, D., Wang, W., A novel coronavirus from patients with pneumonia in China 2019 (2020) N Engl J Med, 382, pp. 727-733; Lu, R., Zhao, X., Li, J., Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding (2020) Lancet, 395, pp. 565-574; World Health Organization, , https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-At-the-media-briefng-on-covid-19-11-march-2020; Istituto Superiore di Sanità, , https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati; Remuzzi, A., Remuzzi, G., Covid-19 and Italy: What next? (2020) Lancet, , [Epub ahead of print: 13 Mar 2020]; (2020) Gazzetta Uffciale della Repubblica Italiana, , https://www.gazzettauffciale.it/eli/gu/2020/03/09/62/sg/pdf; Li, R., Pei, S., Chen, B., Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (sars-cov2) (2020) Science, 6, p. eabb3221; Spina, S., Marrazzo, F., Migliari, M., The response of milan's emergency medical system to the covid-19 outbreak in Italy (2020) Lancet, 395, pp. e49-e50; Grasselli, G., Pesenti, A., Cecconi, M., Critical care utilization for the covid-19 outbreak in lombardy Italy: Early experience and forecast during an emergency response (2020) JAMA, , [Epub ahead of print: 13 Mar 2020]; Murthy, S., Gomersall, C.D., Fowler, R.A., Care for critically ill patients with covid-19 (2020) JAMA, , [Epub ahead of print: 11 Mar 2020]; Wu, Z., McGoogan, J.M., Characteristics of and important lessons from the coronavirus disease 2019 (covid-19) outbreak in China: Summary of a report of 72 314 cases from the chinese center for disease control and prevention (2020) JAMA, , [Epub ahead of print: 13 Mar 2020]; Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2020 (2020) CA Cancer J Clin, 70, pp. 7-30; Kamboj, M., Sepkowitz, K.A., Nosocomial infections in patients with cancer (2009) Lancet Oncol, 10, pp. 589-597; Liang, W., Guan, W., Chen, R., Cancer patients in sars-cov-2 infection: A nationwide analysis in China (2020) Lancet Oncol, 21, pp. 335-337; Xia, Y., Jin, R., Zhao, J., Risk of covid-19 for cancer patients (2020) Lancet Oncol, , [Epub ahead of print: 03 Mar 2020]; Ueda, M., Martins, R., Hendrie, P.C., Managing cancer care during the covid-19 pandemic: Agility and collaboration toward a common goal (2020) J Natl Compr Cancer Netw; Rischio Infettivo da Coronavirus COVID 19: Indicazioni per l'Oncologia da Parte Del Presidente AIOM, Del Presidente Eletto AIOM, Del Presidente CIPOMO e Del Presidente COMU, , https://www.aiom.it/wp-content/uploads/2020/03/20200313-COVID-19-indicazioni-AIOM-CIPOMO-COMU.pdf; Mehta, P., McAuley, D.F., Brown, M., Covid-19: Consider cytokine storm syndromes and immunosuppression (2020) Lancet, , [Epub ahead of print: 16 Mar 2020]; Francesco, C., Pettke, A., Michele, B., Managing covid-19 in the oncology clinic and avoiding the distraction effect (2020) Ann Oncol, , [Epub ahead of print: 19 Mar 2020]; Hollander, J.E., Carr, B.G., Virtually perfect? Telemedicine for covid-19 (2020) N Engl J Med, , [Epub ahead of print: 11 Mar 2020]; Food and Drug Administration (FDA), , https://www.fda.gov/media/136238/download; European Medicines Agency (EMA), , https://www.ema.europa.eu/en/news/guidance-sponsors-how-manage-clinical-trials-during-covid-19-pandemi; Agenzia Italiana Del Farmaco (AIFA), , https://www.aifa.gov.it/documents/20142/871583/Comunicato-gestione-studi-clinici-in-emergenza-COVID-19-EN-12.03.2020.pdf/ee1f33e3-bb3e-9ce9-2a93-b33e88eea94d

PY - 2020

Y1 - 2020

KW - editorial

KW - age

KW - Article

KW - cancer growth

KW - cancer immunotherapy

KW - cancer palliative therapy

KW - cancer patient

KW - cancer screening

KW - cancer therapy

KW - caregiver

KW - coronavirus disease 2019

KW - cytokine storm

KW - differential diagnosis

KW - European Medicines Agency

KW - evidence based practice

KW - follow up

KW - Food and Drug Administration

KW - health care personnel

KW - hospital admission

KW - human

KW - infection risk

KW - Italy

KW - malignant neoplasm

KW - medical oncologist

KW - pandemic

KW - risk factor

KW - telemedicine

KW - terminal care

KW - therapy delay

KW - treatment interruption

KW - virus pneumonia

KW - virus transmission

KW - Betacoronavirus

KW - China

KW - Coronavirinae

KW - Coronavirus infection

KW - oncologist

KW - SARS coronavirus

KW - Coronavirus

KW - Coronavirus Infections

KW - Humans

KW - Oncologists

KW - Pandemics

KW - Pneumonia, Viral

KW - SARS Virus

U2 - 10.1136/esmoopen-2020-000759

DO - 10.1136/esmoopen-2020-000759

M3 - Article

VL - 5

JO - ESMO Open

JF - ESMO Open

SN - 2059-7029

IS - 2

ER -